In a first, retinal nerve cells grown in lab

Image
IANS New York
Last Updated : Dec 01 2015 | 12:13 PM IST

Researchers from Johns Hopkins University have developed a method to efficiently turn human stem cells into retinal nerve cells that transmit visual signals from the eye to the brain.

Death and dysfunction of these cells cause vision loss in conditions like glaucoma and multiple sclerosis (MS).

"Our work could lead not only to a better understanding of the biology of the optic nerve, but also to a cell-based human model that could be used to discover drugs that stop or treat blinding conditions," said study leader Donald Zack from Johns Hopkins' School of Medicine.

Eventually, it could lead to the development of cell transplant therapies that restore vision in patients with glaucoma and MS.

Using a genome editing laboratory tool, investigators inserted a fluorescent protein gene into the stem cells' DNA.

They used a technique called fluorescence-activated cell sorting to separate out the newly differentiated retinal ganglion (nerve) cells from a mixture of different cells into a highly purified cell population for study.

"The cells showed biological and physical properties seen in retinal ganglion cells produced naturally," Zack noted.

Researchers also found that adding a naturally occurring plant chemical called forskolin on the first day of the process helped improve the cells' efficiency of becoming retinal ganglion cells.

The researchers, however, caution that forskolin which is used for weight loss and muscle building, is not scientifically proven safe or effective for treatment or prevention of blindness or any other disorder.

"By the 30th day of culture, there were obvious clumps of fluorescent cells visible under the microscope," noted lead author Valentin Sluch, now a postdoctoral scholar working at Novartis, a pharmaceutical company.

In follow-up studies, the team is looking to find other genes that are important for ganglion cell survival and function.

"We hope that these cells can eventually lead to new treatments for glaucoma and other forms of optic nerve disease," the authors noted in a paper appeared in the journal Scientific Reports.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 01 2015 | 12:02 PM IST

Next Story